Genetic Interactions in Cancer Progression and Treatment

Overview

Journal Cell

Publisher Cell Press

Specialty Cell Biology

Date 2011 Apr 5

PMID 21458666

Citations 205

Authors

Alan Ashworth

Christopher J Lord

Jorge S Reis-Filho

Affiliations

Soon will be listed here.

Abstract

As cancer cell genomes are unveiled at a breathtaking pace, the genetic principles at play in cancer are emerging in all their complexity, prompting the assessment of classical genetic interaction models. Here, we discuss the implications of these findings for cancer progression and heterogeneity and for the development of new therapeutic approaches.

Citing Articles

Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers.

Moser S, Jonkers J Cancer Discov. 2025; 15(3):461-480.

PMID: 40025950 PMC: 11893084. DOI: 10.1158/2159-8290.CD-24-1326.

Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials.

Zhang H, Rutkowska A, Gonzalez-Martin A, Mirza M, Monk B, Vergote I Cancer Res Commun. 2024; 5(1):178-186.

PMID: 39636225 PMC: 11775730. DOI: 10.1158/2767-9764.CRC-24-0191.

Graphlet-based hyperbolic embeddings capture evolutionary dynamics in genetic networks.

Windels S, Tello Velasco D, Rotkevich M, Malod-Dognin N, Przulj N Bioinformatics. 2024; 40(11).

PMID: 39495120 PMC: 11568109. DOI: 10.1093/bioinformatics/btae650.

Synthesis and In Silico Evaluation of Piperazine-Substituted 2,3-Dichloro-5,8-dihydroxy-1,4-naphthoquinone Derivatives as Potential PARP-1 Inhibitors.

Nemetova U, Si Yah P, Boran T, Bi Lgi C, Ozyurek M, Sahi Nler Ayla S ACS Omega. 2024; 9(38):39733-39742.

PMID: 39346823 PMC: 11425603. DOI: 10.1021/acsomega.4c04915.

Molecular mechanism of PARP inhibitor resistance.

Huang Y, Chen S, Yao N, Lin S, Zhang J, Xu C Oncoscience. 2024; 11:69-91.

PMID: 39318358 PMC: 11420906. DOI: 10.18632/oncoscience.610.